Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard Anticipating Endoscopic Suturing Device Sales By Second Quarter 2000

This article was originally published in The Gray Sheet

Executive Summary

Bard expects to add roughly $5 mil. to its top line during the first year of sales of its endoscopic suturing device for treatment of severe gastroesophageal reflux disease (GERD).

You may also be interested in...



C.R.Bard

Firm plans to launch palladium and iodine brachytherapy seeds for treatment of benign prostatic hyperplasia by the end of the second quarter, company Chairman and CEO William Longfield reports at a Feb. 2 session of the U.S. Bancorp Piper Jaffray Health Care Conference in New York City. The firm will "accelerate [its] position to market very quickly," Longfield notes. Separately, Bard expects to commence by mid-February a Phase II clinical trial of an endoluminal graft for minimally invasive treatment of abdominal aortic aneurysms. The company had announced an exclusive agreement with California-based Endologix on Aug. 16 for distribution rights in Europe and Australia (1"The Gray Sheet" Sept. 20, p. 13). Longfield reiterates a previous pledge to buy Endologix this year

C.R.Bard

Firm plans to launch palladium and iodine brachytherapy seeds for treatment of benign prostatic hyperplasia by the end of the second quarter, company Chairman and CEO William Longfield reports at a Feb. 2 session of the U.S. Bancorp Piper Jaffray Health Care Conference in New York City. The firm will "accelerate [its] position to market very quickly," Longfield notes. Separately, Bard expects to commence by mid-February a Phase II clinical trial of an endoluminal graft for minimally invasive treatment of abdominal aortic aneurysms. The company had announced an exclusive agreement with California-based Endologix on Aug. 16 for distribution rights in Europe and Australia (1"The Gray Sheet" Sept. 20, p. 13). Longfield reiterates a previous pledge to buy Endologix this year

Conway Stuart Stretta GERD Clearance Expected By April 2000

Conway Stuart's Stretta radiofrequency ablation catheter and control module could gain 510(k) approval for the treatment of gastroesophageal reflux disease (GERD) as early as April 2000, company founder Stuart Edwards reported Oct. 28.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel